Kfar-Sava, Israel Clinical Trials

A listing of Kfar-Sava, Israel clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
A Study of WVT078 in Patients With Multiple Myeloma (MM)

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

immunomodulatory imide drug
refractory multiple myeloma
proteasome inhibitor
Novartis Investigative Site
 (9.7 away) Contact site
  • 8 views
  • 20 Sep, 2021
  • +13 other locations
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

leukemia
lymphoma
lymphoid leukemia
hodgkin's disease
chronic lymphocytic leukemia
Novartis Investigative Site
 (9.7 away) Contact site
  • 5 views
  • 04 Aug, 2021
  • +10 other locations
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

trametinib
melanoma skin
stage iv non-small cell lung cancer
BRAF
malignant melanoma of skin
Novartis Investigative Site
 (9.2 away) Contact site
  • 272 views
  • 19 Sep, 2021
  • +35 other locations
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

adenocarcinoma
solid neoplasm
targeted therapy
primary cancer
Sourasky Medical Center
 (9.7 away) Contact site
  • 17 views
  • 15 Sep, 2021
  • +10 other locations
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

major surgery
denosumab
aptt
durvalumab
anticoagulants
Sheba Medical Center
 (9.0 away) Contact site
  • 1 views
  • 26 Jan, 2021
  • +2 other locations
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 …

Rabin Medical Center
 (6.6 away) Contact site
  • 0 views
  • 14 May, 2021
  • 1 location
Safety and Efficacy of the ElastiMed's SACS 2.0 - Smart Active Compression Stocking for the Treatment of Venous Edema

Device Efficacy: The primary efficacy assessment will be defined as successful if the edema volume will be reduced over time after using the SACS 2.0 device. Treatment and edema evaluation will be performed in comparison to a standard compression bandage. The treatment will be performed for several hours during the …

Sheba Medical Center at Tel HaShomer
 (9.0 away) Contact site
  • 0 views
  • 17 Apr, 2021
  • 1 location
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

This phase 1, open-label, single-arm, prospective, single center study will evaluate the safety, tolerability and efficacy of cyclosporine in combination with carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM).

Tel Aviv Sourasky Medical Center
 (9.7 away) Contact site
  • 0 views
  • 01 May, 2021
  • 1 location
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without …

immunomodulators
risankizumab
enteropathy
aminosalicylates
vitamin
Sheba Medical Center /ID# 223959
 (9.0 away) Contact site
  • 113 views
  • 31 Aug, 2021
  • +6 other locations
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions: …

liver metastasis
oophorectomy
calcium
biomarker analysis
nivolumab
Sheba Medical Center
 (9.6 away) Contact site
  • 56 views
  • 02 Apr, 2021
  • 1 location